Gabriel Cabot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5483972/publications.pdf

Version: 2024-02-01

53 papers	3,442 citations	136740 32 h-index	155451 55 g-index
56 all docs	56 docs citations	56 times ranked	3031 citing authors

#	Article	IF	Citations
1	Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. Journal of Antimicrobial Chemotherapy, 2022, 77, 957-968.	1.3	14
2	Molecular mechanisms driving thein vivodevelopment of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDRPseudomonas aeruginosainfections. Journal of Antimicrobial Chemotherapy, 2021, 76, 91-100.	1.3	38
3	In vitroevolution of cefepime/zidebactam (WCK 5222) resistance inPseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact onin vivoefficacy. Journal of Antimicrobial Chemotherapy, 2021, 76, 2546-2557.	1.3	11
4	Whole-genome sequence-guided PCR for the rapid identification of thePseudomonas aeruginosaST175 high-risk clone directly from clinical samples. Journal of Antimicrobial Chemotherapy, 2021, 76, 945-949.	1.3	2
5	Weighting the impact of virulence on the outcome of Pseudomonas aeruginosa bloodstream infections. Clinical Microbiology and Infection, 2020, 26, 351-357.	2.8	11
6	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	50
7	Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection. Journal of Antimicrobial Chemotherapy, 2020, 75, 3209-3217.	1.3	26
8	Nosocomial outbreak linked to a flexible gastrointestinal endoscope contaminated with an amikacin-resistant ST17 clone of Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 1837-1844.	1.3	11
9	In vitro dynamics and mechanisms of resistance development to imipenem and imipenem/relebactam in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 2508-2515.	1.3	24
10	Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic Î²-Lactam-Resistant Mutants. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	54
11	Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2020, 75, 1474-1478.	1.3	26
12	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y MicrobiologÃ¤ ClÃ¤nica, 2020, 38, 474-478.	0.3	13
13	Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learningâ€enabled molecular diagnostics. EMBO Molecular Medicine, 2020, 12, e10264.	3.3	111
14	Characterization of AmpC Î²-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane/tazobactam during therapy. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2020, 38, 474-478.	0.2	1
15	Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. Journal of Antimicrobial Chemotherapy, 2019, 74, 3217-3220.	1.3	18
16	Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	22
17	Comparative Analysis of Peptidoglycans From Pseudomonas aeruginosa Isolates Recovered From Chronic and Acute Infections. Frontiers in Microbiology, 2019, 10, 1868.	1.5	12
18	Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835.	1.3	92

#	Article	IF	Citations
19	Profiling the susceptibility of Pseudomonas aeruginosa strains from acute and chronic infections to cell-wall-targeting immune proteins. Scientific Reports, 2019, 9, 3575.	1.6	10
20	In Vitro and In Vivo Activities of Î²-Lactams in Combination with the Novel Î²-Lactam Enhancers Zidebactam and WCK 5153 against Multidrug-Resistant Metallo-Î²-Lactamase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
21	Evolution of the Pseudomonas aeruginosa Aminoglycoside Mutational Resistome In Vitro and in the Cystic Fibrosis Setting. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	44
22	Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 658-663.	1.3	157
23	Deciphering Î²-lactamase-independent Î²-lactam resistance evolution trajectories in Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 3322-3331.	1.3	27
24	The Versatile Mutational Resistome of Pseudomonas aeruginosa. Frontiers in Microbiology, 2018, 9, 685.	1.5	181
25	Understanding the acute inflammatory response to Pseudomonas aeruginosa infection: differences between susceptible and multidrug-resistant strains in a mouse peritonitis model. International Journal of Antimicrobial Agents, 2017, 49, 198-203.	1.1	12
26	Interplay among Resistance Profiles, High-Risk Clones, and Virulence in the Caenorhabditis elegansPseudomonas aeruginosa Infection Model. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	39
27	Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	108
28	Evolution of the Pseudomonas aeruginosa mutational resistome in an international Cystic Fibrosis clone. Scientific Reports, 2017, 7, 5555.	1.6	117
29	In Vivo Emergence of Resistance to Novel Cephalosporinâ€“Î²-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 Î²-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	61
30	Targeting the permeability barrier and peptidoglycan recycling pathways to disarm Pseudomonas aeruginosa against the innate immune system. PLoS ONE, 2017, 12, e0181932.	1.1	32
31	Impact of multidrug resistance on the pathogenicity of Pseudomonas aeruginosa: in vitro and in vivo studies. International Journal of Antimicrobial Agents, 2016, 47, 368-374.	1.1	30
32	Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections. Antimicrobial Agents and Chemotherapy, 2016, 60, 2912-2922.	1.4	25
33	Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing. Antimicrobial Agents and Chemotherapy, 2016, 60, 7415-7423.	1.4	99
34	Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant Î²-Lactam Resistance Mechanisms. Antimicrobial Agents and Chemotherapy, 2016, 60, 6407-6410.	1.4	47
35	Impact of AmpC Derepression on Fitness and Virulence: the Mechanism or the Pathway?. MBio, 2016, 7, .	1.8	62
36	Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates. Antimicrobial Agents and Chemotherapy, 2016, 60, 1767-1778.	1.4	170

#	Article	IF	Citations
37	Role of Pseudomonas aeruginosa Low-Molecular-Mass Penicillin-Binding Proteins in AmpC Expression, Î²-Lactam Resistance, and Peptidoglycan Structure. Antimicrobial Agents and Chemotherapy, 2015, 59, 3925-3934.	1.4	75
38	N-Acetylcysteine Selectively Antagonizes the Activity of Imipenem in Pseudomonas aeruginosa by an OprD-Mediated Mechanism. Antimicrobial Agents and Chemotherapy, 2015, 59, 3246-3251.	1.4	16
39	Draft Genome Sequence of the Quorum-Sensing and Biofilm-Producing Pseudomonas aeruginosa Strain Pae221, Belonging to the Epidemic High-Risk Clone Sequence Type 274. Genome Announcements, 2015, 3, .	0.8	5
40	Influence of Virulence Genotype and Resistance Profile in the Mortality of Pseudomonas aeruginosa Bloodstream Infections. Clinical Infectious Diseases, 2015, 60, 539-548.	2.9	153
41	Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC. Antimicrobial Agents and Chemotherapy, 2014, 58, 3091-3099.	1.4	197
42	Biological Markers of Pseudomonas aeruginosa Epidemic High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2013, 57, 5527-5535.	1.4	104
43	A trade-off between oxidative stress resistance and DNA repair plays a role in the evolution of elevated mutation rates in bacteria. Proceedings of the Royal Society B: Biological Sciences, 2013, 280, 20130007.	1.2	40
44	Clonal Dissemination, Emergence of Mutator Lineages and Antibiotic Resistance Evolution in Pseudomonas aeruginosa Cystic Fibrosis Chronic Lung Infection. PLoS ONE, 2013, 8, e71001.	1.1	69
45	Alterations of OprD in Carbapenem-Intermediate and -Susceptible Strains of Pseudomonas aeruginosa Isolated from Patients with Bacteremia in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2012, 56, 1703-1713.	1.4	111
46	Genetic Markers of Widespread Extensively Drug-Resistant Pseudomonas aeruginosa High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2012, 56, 6349-6357.	1.4	189
47	Pan-Î²-Lactam Resistance Development in Pseudomonas aeruginosa Clinical Strains: Molecular Mechanisms, Penicillin-Binding Protein Profiles, and Binding Affinities. Antimicrobial Agents and Chemotherapy, 2012, 56, 4771-4778.	1.4	138
48	Wide Dispersion of ST175 Clone despite High Genetic Diversity of Carbapenem-Nonsusceptible Pseudomonas aeruginosa Clinical Strains in 16 Spanish Hospitals. Journal of Clinical Microbiology, 2011, 49, 2905-2910.	1.8	76
49	Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study. Antimicrobial Agents and Chemotherapy, 2011, 55, 1906-1911.	1.4	168
50	Environmental Microbiota Represents a Natural Reservoir for Dissemination of Clinically Relevant Metallo-Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2011, 55, 5376-5379.	1.4	55
51	Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. Journal of Antimicrobial Chemotherapy, 2011, 66, 2022-2027.	1.3	132
52	AmpG Inactivation Restores Susceptibility of Pan-Î²-Lactam-Resistant Pseudomonas aeruginosa Clinical Strains. Antimicrobial Agents and Chemotherapy, 2011, 55, 1990-1996.	1.4	47
53	NagZ Inactivation Prevents and Reverts Î²-Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2010, 54, 3557-3563.	1.4	61